QTX3046 in Patients With KRAS G12D Mutations
NCT06428500
·
clinicaltrials.gov ↗
PHASE1
Phase
ACTIVE_NOT_RECRUITING
Status
240
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumor
Interventions
DRUG:
QTX3046
COMBINATION_PRODUCT:
Cetuximab
Sponsor
Quanta Therapeutics